Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Glenmark Life Sciences Limited (GLS) - Total Assets
Latest total assets as of September 2024: ₹30.85 Billion INR
Based on the latest financial reports, Glenmark Life Sciences Limited (GLS) holds total assets worth ₹30.85 Billion INR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Glenmark Life Sciences Limited - Total Assets Trend (2018–2024)
This chart illustrates how Glenmark Life Sciences Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Glenmark Life Sciences Limited - Asset Composition Analysis
Current Asset Composition (March 2024)
Glenmark Life Sciences Limited's total assets of ₹30.85 Billion consist of 67.2% current assets and 32.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 10.6% |
| Accounts Receivable | ₹7.65 Billion | 26.9% |
| Inventory | ₹6.67 Billion | 23.4% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹148.53 Million | 0.5% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Glenmark Life Sciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Glenmark Life Sciences Limited's current assets represent 67.2% of total assets in 2024, a decrease from 98.8% in 2018.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2024, up from 8.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 26.9% of total assets.
Glenmark Life Sciences Limited Competitors by Total Assets
Key competitors of Glenmark Life Sciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Glenmark Life Sciences Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Glenmark Life Sciences Limited generates 0.80x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Glenmark Life Sciences Limited generates $ 16.52 in net profit.
Glenmark Life Sciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.52 | 4.16 | 1.07 |
| Quick Ratio | 3.03 | 2.82 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹16.32 Billion | ₹ 15.78 Billion | ₹ 886.17 Million |
Glenmark Life Sciences Limited - Advanced Valuation Insights
This section examines the relationship between Glenmark Life Sciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.47 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | ₹28.50 Billion |
| Market Capitalization | $389.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Glenmark Life Sciences Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Glenmark Life Sciences Limited's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Glenmark Life Sciences Limited (2018–2024)
The table below shows the annual total assets of Glenmark Life Sciences Limited from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | ₹28.50 Billion | +5.49% |
| 2023-03-31 | ₹27.02 Billion | +9.35% |
| 2022-03-31 | ₹24.71 Billion | +23.73% |
| 2021-03-31 | ₹19.97 Billion | +15.73% |
| 2020-03-31 | ₹17.26 Billion | +16.96% |
| 2019-03-31 | ₹14.75 Billion | +1735658.82% |
| 2018-03-31 | ₹850.00K | -- |